Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...316317318319320321322323324325326...10671068»
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Drug-loaded mesoporous silica on carboxymethyl cellulose hydrogel: development of innovative 3D printed hydrophilic films. (Pubmed Central) -  May 18, 2022   
    The 3D printed films showed complete drug release after 12 h, and the presence of the triamcinolone acetonide-loaded SBA-15 improved their in vitro mucoadhesion, suggesting their promising application in oral mucosa treatments. Besides representing an innovative platform to develop water-based mucoadhesive formulations containing a hydrophobic drug, this is the first report proposing the development of SSE 3D printed nanomedicines containing drug-loaded mesoporous silica.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. (Pubmed Central) -  May 18, 2022   
    Aiming to reduce mortality in COVID-19 with severe respiratory failure we administered a combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone/heparin) consisted of inhaled DNase to dissolve thrombogenic neutrophil extracellular traps, plus agents against cytokine-mediated hyperinflammation, namely anti-IL-6-receptor tocilizumab and JAK1/2 inhibitor baricitinib...COMBI group (n = 22) was compared with similar groups that had received SOC alone (n = 26) or SOC plus monotherapy with either IL-1-receptor antagonist anakinra (n = 19) or tocilizumab (n = 11)...This effect was inhibited by the immunomodulatory agents of COMBI providing a mechanistic explanation for the clinical observations. These results support the conduct of randomized trials using combined immunomodulation in COVID-19 to target multiple interconnected pathways of immunothrombosis.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Preclinical, Journal:  Effect of fire needling on imiquimod induced psoriasis-like lesion and STAT3 pathway in mice (Pubmed Central) -  May 18, 2022   
    Fire needling therapy improves skin lesion severity in imiquimod induced psoriasis-like lesion of the mice, which is probably related to the inhibition of STAT3 pathway activation and the decrease of Th17 inflammatory factors expression. The systemic regulation of fire needling at "Dazhui" (GV 14) and "Zusanli" (ST 36) is superior to the local treatment.
  • ||||||||||  dexamethasone / Generic mfg., dexamethasone injection / Generic mfg.
    Trial completion date, Trial termination:  Palliative Management of Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) -  May 18, 2022   
    P2,  N=15, Terminated, 
    No abstract available Trial completion date: Dec 2022 --> Sep 2021 | Active, not recruiting --> Terminated; low accrual
  • ||||||||||  pomalidomide / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice (clinicaltrials.gov) -  May 18, 2022   
    P=N/A,  N=150, Recruiting, 
    Trial completion date: Dec 2022 --> Sep 2021 | Active, not recruiting --> Terminated; low accrual Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Dec 2023
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Use Lenalidomide (Revlimid (clinicaltrials.gov) -  May 18, 2022   
    P=N/A,  N=29, Active, not recruiting, 
    Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Dec 2023 Recruiting --> Active, not recruiting | N=112 --> 29 | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2021 --> Aug 2022
  • ||||||||||  relacorilant (CORT125134) / Corcept Therap
    Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases:  RELIANT: Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  May 18, 2022   
    P3,  N=43, Terminated, 
    N=80 --> 43 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2022 --> Aug 2021; The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
    Trial completion date, Trial primary completion date, Real-world evidence, Patient reported outcomes, Real-world:  RECORD: REported Outcomes in COPD With Trixeo in Real worlD (clinicaltrials.gov) -  May 17, 2022   
    P=N/A,  N=500, Not yet recruiting, 
    Although our evaluation is limited to three covid-19 treatments, these findings suggest that meta-analyzed evidence from observational studies might complement, but should not replace, evidence collected from RCTs. Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2023
  • ||||||||||  Enrollment status:  Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (clinicaltrials.gov) -  May 17, 2022   
    P2,  N=60, Enrolling by invitation, 
    Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2023 Recruiting --> Enrolling by invitation
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  QT interval instability and variability in dogs with naturally-occurring hypercortisolism. (Pubmed Central) -  May 17, 2022   
    The NOHC group was subdivided according to cortisol suppression pattern in the low-dose dexamethasone suppression test...There was no statistical difference between sex groups in any of the electrocardiographic parameters studied. This result might indicate that the etiology of NOHC, and its consequent influence on hypothalamus-pituitary-adrenal axis could interfere on the heterogeneity of ventricular repolarization parameters in different ways, especially in the short-term and the long-term stability; however further studies are necessary to understand the role of cortisol on electrical instability in dogs.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment open, Trial completion date, Trial primary completion date:  Ra-P-OCD: Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement (clinicaltrials.gov) -  May 17, 2022   
    P2,  N=40, Enrolling by invitation, 
    A critical element in cases such as this one is that treatment decisions are made by a team of specialists, including pulmonologists. Not yet recruiting --> Enrolling by invitation | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT) (clinicaltrials.gov) -  May 17, 2022   
    P3,  N=690, Completed, 
    Not yet recruiting --> Enrolling by invitation | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: Apr 2025 --> Apr 2026 Recruiting --> Completed | Trial completion date: Oct 2021 --> May 2022 | Trial primary completion date: Aug 2021 --> May 2022
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Phase classification:  ICOMI: Soft Part Management for Surgical Fractures of the Lower Limb (clinicaltrials.gov) -  May 16, 2022   
    P=N/A,  N=120, Recruiting, 
    Suspended --> Recruiting | N=15 --> 40 Phase classification: P3 --> P=N/A